# Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer

> **NCT02489357** · NA · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 12 (actual)

## Conditions studied

- Stage IV Prostate Cancer

## Interventions

- **PROCEDURE:** Cryosurgery
- **DRUG:** Degarelix
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02489357
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-11
- **Primary completion:** 2017-11-30
- **Final completion:** 2017-11-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02489357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02489357, "Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02489357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*